期刊
BIOMOLECULES
卷 12, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/biom12010034
关键词
RTP801; REDD1; Huntington's disease; neuroinflammation; hippocampus; cognitive dysfunction
资金
- Spanish Ministry of Science, Innovation, and Universities grants [SAF2017-88812 R, PID2020-119236RB-I00, RTI2018-094678-A-I00, SAF2017-88076, PID2020-119386R-100, RYC-2016-19466]
- Portal d'Avall S.L
RTP801 is increased in neurodegenerative diseases and its downregulation can improve behavioral abnormalities. This study found that RTP801 levels are increased in the hippocampus of HD patients, correlated with gliosis markers. Silencing RTP801 in the dorsal hippocampus of HD mouse models improved cognitive alterations and reduced inflammation.
RTP801/REDD1 is a stress-regulated protein whose levels are increased in several neurodegenerative diseases such as Parkinson's, Alzheimer's, and Huntington's diseases (HD). RTP801 downregulation ameliorates behavioral abnormalities in several mouse models of these disorders. In HD, RTP801 mediates mutant huntingtin (mhtt) toxicity in in vitro models and its levels are increased in human iPSCs, human postmortem putamen samples, and in striatal synaptosomes from mouse models of the disease. Here, we investigated the role of RTP801 in the hippocampal pathophysiology of HD. We found that RTP801 levels are increased in the hippocampus of HD patients in correlation with gliosis markers. Although RTP801 expression is not altered in the hippocampus of the R6/1 mouse model of HD, neuronal RTP801 silencing in the dorsal hippocampus with shRNA containing AAV particles ameliorates cognitive alterations. This recovery is associated with a partial rescue of synaptic markers and with a reduction in inflammatory events, especially microgliosis. Altogether, our results indicate that RTP801 could be a marker of hippocampal neuroinflammation in HD patients and a promising therapeutic target of the disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据